Polydex Pharmaceuticals Valuation
| POLXFDelisted Stock | USD 1.96 0.01 0.51% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Polydex Pharmaceuticals holds a recent Real Value of $1.6 per share. The prevailing price of the company is $1.96. Our model determines the value of Polydex Pharmaceuticals from analyzing the company fundamentals such as Shares Outstanding of 3.43 M, operating margin of (0.22) %, and Return On Equity of -0.18 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Polydex Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Polydex Pharmaceuticals is based on 3 months time horizon. Increasing Polydex Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Polydex pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Polydex Pharmaceuticals. Since Polydex Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Polydex Pink Sheet. However, Polydex Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.96 | Real 1.6 | Hype 1.96 | Naive 1.99 |
The real value of Polydex Pink Sheet, also known as its intrinsic value, is the underlying worth of Polydex Pharmaceuticals Company, which is reflected in its stock price. It is based on Polydex Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Polydex Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Polydex Pharmaceuticals helps investors to forecast how Polydex pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Polydex Pharmaceuticals more accurately as focusing exclusively on Polydex Pharmaceuticals' fundamentals will not take into account other important factors: Polydex Pharmaceuticals Total Value Analysis
Polydex Pharmaceuticals is at this time anticipated to have takeover price of 2.23 M with market capitalization of 2.23 M, debt of 301.49 K, and cash on hands of 870.3 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Polydex Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.23 M | 2.23 M | 301.49 K | 870.3 K |
Polydex Pharmaceuticals Investor Information
The company has price-to-book ratio of 0.42. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Polydex Pharmaceuticals recorded a loss per share of 0.13. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 23rd of June 1997. Based on the key indicators related to Polydex Pharmaceuticals' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Polydex Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Polydex Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Polydex Pharmaceuticals has an asset utilization ratio of 61.79 percent. This implies that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that Polydex Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Polydex Pharmaceuticals Profitability Analysis
The company reported the revenue of 4.05 M. Net Income was 0 with profit before overhead, payroll, taxes, and interest of 970.3 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Polydex Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Polydex Pharmaceuticals and how it compares across the competition.
About Polydex Pharmaceuticals Valuation
The pink sheet valuation mechanism determines Polydex Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Polydex Pharmaceuticals. We calculate exposure to Polydex Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Polydex Pharmaceuticals's related companies.Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada. Polydex Pharm operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 21 people.
8 Steps to conduct Polydex Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Polydex Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Polydex Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Polydex Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Polydex Pharmaceuticals' revenue streams: Identify Polydex Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Polydex Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Polydex Pharmaceuticals' growth potential: Evaluate Polydex Pharmaceuticals' management, business model, and growth potential.
- Determine Polydex Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Polydex Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Polydex Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Polydex Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Quarterly Earnings Growth Y O Y | -0.374 | |
| Retained Earnings | -18.1 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |